From: New developments in anti-malarial target candidate and product profiles
Profile | Intended use |
---|---|
TPP-1 | Case management; treatment of acute uncomplicated malaria in children or adults. Uses a combination of two or more molecules with TCP-1 activity, plus TCP-5 for reducing transmission and TCP-3 for relapse prevention, when such molecules become available For severe malaria, a parenteral formulation of a single fast-acting TCP-1 would be appropriate |
TPP-2 | Chemoprotection: given to subjects migrating into areas of high endemicity, or during epidemics. Uses a combination of TCP-4 activity, potentially with TCP-1 support for emerging infections |
TCP-1 | Molecules that clear asexual blood-stage parasitemia |
TCP-2 | (profile retired, see body of text) |
TCP-3 | Molecules with activity against hypnozoites (mainly P. vivax) |
TCP-4 | Molecules with activity against hepatic schizonts |
TCP-5 | Molecules that block transmission (targeting parasite gametocytes) |
TCP-6 | Molecules that block transmission by targeting the insect vector (endectocides) |